Press Releases

April 6, 2017 Theratechnologies Announces Financial Results for First Quarter of 2017
March 30, 2017 Theratechnologies to Announce Financial Results for the First Quarter of 2017
March 6, 2017 Theratechnologies Acquires Commercial Rights to Ibalizumab in the European Union and Four Additional Territories
March 1, 2017 Theratechnologies Holds Investment Community Meeting and Provides Updated Financial Guidance for its Fiscal Year 2017
February 24, 2017 Theratechnologies to Host Investment Community Webcast on March 1, 2017
February 15, 2017 Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab.
February 14, 2017 Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
February 8, 2017 Theratechnologies Announces Financial Results for Fiscal Year 2016
December 5, 2016 Theratechnologies closes its offering of common shares
November 25, 2016 Theratechnologies Announces the Filing of a Final Short Form Prospectus
November 14, 2016 Theratechnologies Announces $16.5 Million Bought Deal Financing
November 10, 2016 Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab
November 1, 2016 Theratechnologies Announces Update from its Healthcare Analyst Day Meeting
October 28, 2016 Results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-Breaker Session at IDWeek 2016
October 24, 2016 Theratechnologies Announces End of Patient Treatment for Phase III Ibalizumab Trial
October 4, 2016 Theratechnologies Announces Financial Results for Third Quarter of 2016
September 28, 2016 Theratechnologies to Move Forward with Development of new Single Vial Formulation for EGRIFTA® (Tesamorelin for Injection)
September 1, 2016 Theratechnologies Announces Commercialization Agreement For Tesamorelin In Spain And Portugal
August 18, 2016 Ibalizumab Phase III Study Primary End-Point Results To Be Presented At IDWEEK 2016
July 5, 2016 Theratechnologies Announces Financial Results for Second Quarter of 2016
June 28, 2016 Theratechnologies to announce financial results for the second quarter of 2016
June 9, 2016 Theratechnologies announces regretful decision by the quebec ministry of health
May 24, 2016 Theratechnologies Announces that 82.5% of Patients Achieved the Primary Endpoint in the Phase III Ibalizumab Trial
May 17, 2016 Announcements in conjunction with Theratechnologies annual meeting
May 16, 2016 Update on Tesamorelin Marketing Authorization Application in Brazil
April 28, 2016 Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial
March 31, 2016 Theratechnologies Announces Financial Results for First Quarter of 2016
March 18, 2016 Theratechnologies and TaiMed Biologics sign exclusive Marketing and Distribution Agreement for Ibalizumab
March 8, 2016 Mexico approves the 1mg/vial presentation of EGRIFTA® (tesamorelin for injection)
February 24, 2016 Theratechnologies Announces Financial Results for Fiscal Year 2015
February 24, 2016 Theratechnologies hires new Chief Financial Officer
October 1, 2015 Theratechnologies Announces Financial Results for Third Quarter of 2015
September 1, 2015 Theratechnologies Announces Commercialization Agreement for Tesamorelin in South Korea
August 6, 2015 Theratechnologies Closes its Offering of Units
July 31, 2015 Theratechnologies Announces the Exercise of the Over-Allotment Option
July 30, 2015 Theratechnologies Announces The Filing of a Final Short Form Prospectus (ccn)
July 24, 2015 Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus
July 14, 2015 Theratechnologies Announces Financial Results for Second Quarter of 2015
July 14, 2015 EGRIFTA(TM) (Tesamorelin for Injection) Approved in Mexico
June 25, 2015 Theratechnologies Initiates Canadian Distribution of EGRIFTA(TM) (Tesamorelin for Injection)
June 9, 2015 Tesamorelin to be Assessed in the Treatment of Liver Disease in HIV-Infected Patients
May 20, 2015 Announcements in Conjunction With Theratechnologies Annual Meeting
May 15, 2015 Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted
April 17, 2015 Supreme Court of Canada rules in favour of Theratechnologies
April 14, 2015 Theratechnologies Announces Financial Results for First Quarter of 2015
March 30, 2015 Health Canada Approves 1mg/vial Presentation of EGRIFTA(TM) (tesamorelin for injection)
February 27, 2015 Theratechnologies Annouces Commercialization Agreement for Egriftam (Tesamorelin for injection) in Europe
February 26, 2015 Theratechnologies Announces Financial Results for Fiscal Year 2014
February 3, 2015 Theratechnologies announces voluntary filing of form 15 to suspend SEC reporting obligations
October 8, 2014 Theratechnologies Announces Financial Results for Third Quarter of 2014
September 3, 2014 Theratechnologies resumes distribution of EGRIFTA® (Tesamorelin for injection) in the United States
July 9, 2014 Theratechnologies Announces Financial Results for Second Quarter of 2014
June 25, 2014 Theratechnologies to receive 4.1 million dollar payment from Revenue Canada
June 10, 2014 Theratechnologies Obtains U.S. Patent Term Extension for Tesamorelin
May 23, 2014 Additional Update on Availability of EGRIFTA(R) (tesamorelin for injection) in the United States
May 21, 2014 Announcements in Conjunction With Theratechnologies Annual Meeting
May 20, 2014 Update on Availability of EGRIFTA(TM) in the United States
May 1, 2014 Theratechnologies regains rights to EGRIFTA (tesamorelin for injection) in the United States
April 30, 2014 Health Canada approves EGRIFTA
April 14, 2014 Theratechnologies announces financial results for first quarter of 2014
February 27, 2014 Theratechnologies announces financial results for fiscal year 2013
February 25, 2014 Theratechnologies to announce financial results for fiscal year 2013
February 14, 2014 Short Supply of EGRIFTA ® Announced
December 13, 2013 Theratechnologies regains U.S. marketing rights to Egrifta
December 3, 2013 Theratechnologies resumes shipment of tesamorelin to EMD Serono
November 13, 2013 Jubilant HollisterStier Notifies Theratechnologies of Labour Disruption
November 1, 2013 Health Canada Agrees to Reconsider Tesamorelin
October 10, 2013 Theratechnologies Announces Financial Results for Third Quarter of 2013
October 3, 2013 Theratechnologies to Announce Third Quarter 2013 Financial Results
September 18, 2013 EMD Serono notifies FDA of a Shortage of tesamorelin
September 4, 2013 Theratechnologies Provides Manufacturing Update on EGRIFTA
July 17, 2013 Securities Class Action Update
July 11, 2013 Theratechnologies obtains US Patent for Improving Cognitive Function with Tesamorelin in Patients Suffering from MCI
July 10, 2013 Theratechnologies Announces Financial Results for Second Quarter of 2013
July 8, 2013 Request for Reconsideration in Canada: Meeting With Scientific Advisory Committee Authorized
July 3, 2013 Theratechnologies to Announce Second Quarter 2013 Financial Results
June 28, 2013 Theratechnologies provides regulatory update for Colombia
May 27, 2013 Information on Class Action Motion
May 24, 2013 Announcements in Conjunction With Theratechnologies Annual Meeting
April 11, 2013 Theratechnologies Announces Financial Results for First Quarter of 2013
April 9, 2013 Theratechnologies Board of Directors Appoints Former Merck Canada President
April 8, 2013 Theratechnologies Announces Termination of Agreement With Ferrer
April 3, 2013 Renegotiated Lease to Generate Substantial Annual Savings
March 25, 2013 Health Canada Decision Appealed
March 4, 2013 Health Canada Issues Decision on Tesamorelin
February 27, 2013 Theratechnologies Announces Financial Results for Fiscal Year 2012
February 14, 2013 Theratechnologies to Announce Financial Results for Fiscal Year 2012
February 5, 2013 Theratechnologies Announces Completion of NASDAQ Delisting
January 29, 2013 Theratechnologies Secures US Patent for its Novel Peptide TH1173
January 21, 2013 FDA approves alternative storage conditions for EGRIFTA(TM)
January 14, 2013 Theratechnologies Announces Intent to Voluntarily Delist from NASDAQ
October 30, 2012 Revenue Growth and Expenditure Control at the Core of Revised Business Plan
October 29, 2012 Theratechnologies to Host Conference Call
October 11, 2012 Theratechnologies Announces Financial Results for Third Quarter of 2012
October 11, 2012 Theratechnologies Announces Departure of President and Chief Executive Officer
October 10, 2012 Theratechnologies Provides Follow-Up Regulatory Update on Tesamorelin
October 3, 2012 Theratechnologies to Announce Financial Results for Third Quarter Of 2012
August 7, 2012 Theratechnologies Receives Notification from NASDAQ Relating to Minimum Bid Priceum Bid Price
July 12, 2012 Theratechnologies Announces Financial Results for Second Quarter of 2012
July 9, 2012 Theratechnologies to announce financial results for second quarter of 2012
June 27, 2012 New Phase II, NIH-sponsored study demonstrates metabolic effects of tesamorelin in obese subjects with reduced growth hormone secretion
June 22, 2012 Theratechnologies Provides Regulatory Update on Tesamorelin
June 4, 2012 Tesamorelin Filed for Marketing Approval in Colombia and Venezuela
May 15, 2012 Reminder: Theratechnologies Annual Meeting of Shareholders
May 10, 2012 New GRF Peptide TH1173 Enters Important Pre-Clinical Phase
May 2, 2012 Theratechnologies Annual Meeting of Shareholders: Location Change
April 13, 2012 Theratechnologies Announces Financial Results for First Quarter of 2012
March 28, 2012 Media Advisory: Theratechnologies to Present at Needham Annual Healthcare Conference
February 24, 2012 Theratechnologies: update on motion for authorization to institute class action against the Company
February 23, 2012 Media Advisory: Theratechnologies to Present at RBC Capital Markets Conference
February 21, 2012 Theratechnologies Announces a Supply, Distribution and Licensing Agreement With Actelion Pharmaceuticals Canada
February 8, 2012 Theratechnologies Announces Results for Fiscal Year 2011
January 26, 2012 Theratechnologies to Announce Results for Its 2011 Fiscal Year
December 7, 2011 Theratechnologies to discontinue COPD clinical program and accelerate path to profitability
November 24, 2011 Theratechnologies Wins ADRIQ’s 2011 Product Innovation Award
October 19, 2011 Theratechnologies Announces Application for Registration of Tesamorelin in Mexico
October 13, 2011 Theratechnologies Announces Financial Results for the Third Quarter of 2011: U.S. Sales of EGRIFTA® Driving Revenue Growth
October 6, 2011 Theratechnologies Identifies Second Generation GRF Peptide and Initiates Pre- Clinical Studies
September 6, 2011 Theratechnologies Launches Phase 2 Clinical Trial to Investigate Tesamorelin for the Treatment of COPD-Associated Muscle Wasting
September 1, 2011 Tesamorelin filed for Marketing Authorization in Argentina
August 31, 2011 Tesamorelin filed for Marketing Authorization in Brazil
August 16, 2011 Health Canada Accepts to Review Theratechnologies’ New Drug Submission for EGRIFTA®
July 19, 2011 Results of Independent Study on the Effect of Tesamorelin on Cognitive Function Presented at Conference in France
July 15, 2011 Theratechnologies: Data Unveiled on the Effect of Tesamorelin on Metabolic Risk Factors at Conference in Italy
July 7, 2011 Theratechnologies Announces Financial Results for the Second Quarter of 2011
July 5, 2011 Theratechnologies Announces the Filing of an Application for Registration of Tesamorelin in Israel by Sanofi
June 27, 2011 Tesamorelin Accepted for Review by European Medicines Agency
June 20, 2011 Theratechnologies files New Drug Submission for EGRIFTA® with Health Canada
June 16, 2011 Theratechnologies Rings NASDAQ Opening Bell
June 13, 2011 Theratechnologies Announces NASDAQ Listing
June 6, 2011 Theratechnologies Announces Filing of European Marketing Authorization Application for Tesamorelin
June 2, 2011 Theratechnologies Adopts New R&D Business Model to Strengthen its Growth Potential
May 18, 2011 Theratechnologies Holds Annual and Special Meeting of Shareholders After a Year Marked by Historic Achievement
May 16, 2011 Theratechnologies holds annual and special meeting of shareholders
April 12, 2011 Theratechnologies announces results for the first quarter 2011
March 8, 2011 Theratechnologies decides to withdraw its cross-border offering
February 22, 2011 Theratechnologies files preliminary prospectus for cross-border offering
February 22, 2011 Theratechnologies announces new clinical program in muscle wasting in Chronic Obstructive Pulmonary Disease (COPD)
February 9, 2011 Theratechnologies announces results for the 2010 fiscal year
February 3, 2011 Theratechnologies and Ferrer Announce a Distribution & Licensing Agreement for Tesamorelin in Europe
December 6, 2010 Theratechnologies announces a distribution and licensing agreement for EGRIFTATM in Latin America, Africa and the Middle East with sanofi-aventis
December 2, 2010 Theratechnologies plans early adoption of International Financial Reporting Standards
December 1, 2010 Theratechnologies welcomes the arrival of its new President and CEO
November 11, 2010 FDA Approves EGRIFTATM (tesamorelin for injection): The First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-Infected Patients with Lipodystrophy
October 14, 2010 Theratechnologies announces the retirement date for the President and CEO: Mr. Yves Rosconi
October 12, 2010 Theratechnologies announces results for the third quarter 2010 Lower burn rate and solid financial position
September 13, 2010 Theratechnologies: tesamorelin data presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy 50th annual meeting
September 1, 2010 Theratechnologies is pleased to announce the appointment of a new president and CEO
July 26, 2010 Theratechnologies receives a motion of authorization to institute a class action
July 20, 2010 Update on timeline for FDA Action Date for Theratechnologies’ tesamorelin New Drug Application
July 7, 2010 Second Quarter 2010: Theratechnologies Reports Lower Burn Rate and Good Financial Position
June 29, 2010 Theratechnologies added to the Russell Global Index
June 24, 2010 Theratechnologies Announces Publication of Combined Tesamorelin Phase 3 Results in JCEM
June 2, 2010 Yves Rosconi, President & CEO of Theratechnologies, will retire on December 31, 2010
May 27, 2010 Theratechnologies Announces Positive Vote by FDA Advisory Committee for Tesamorelin
March 25, 2010 Theratechnologies Reports Positive Outcome at its Annual and Special Meeting of Shareholders
March 23, 2010 Theratechnologies Announces Financial Results and Closes The First Quarter in a Strong Financial Position
March 22, 2010 FDA Confirms Date for Advisory Committee Review of the Tesamorelin New Drug Application
March 1, 2010 Theratechnologies Announces Publication of Second Phase 3 Results in Jaids
February 28, 2010 Theratechnologies Announces a Tentative New Date for the FDA Advisory Committee Review of the Tesamorelin New Drug Application
February 10, 2010 Milestones Met In 2009 Lead to Optimistic Outlook for Theratechnologies
February 10, 2010 Theratechnologies Adopts Shareholder Rights Plan
January 25, 2010 Theratechnologies Reports that the FDA will Reschedule for Administrative Reasons the Advisory Committee Meeting to Review Tesamorelin’s NDA
January 18, 2010 Theratechnologies Reports Date for FDA Advisory Committee Review of the Tesamorelin New Drug Application
December 29, 2009 Theratechnologies receives patent protection in Brazil for tesamorelin
November 11, 2009 Theratechnologies presents combined Phase 3 clinical results at European AIDS Conference
November 5, 2009 Theratechnologies’ NDA for Tesamorelin to be Reviewed by an FDA Advisory Committee
October 26, 2009 Theratechnologies presents clinically relevant improvements in patient reported outcome parameters
October 5, 2009 Theratechnologies Announces Financial Results for the Third Quarter 2009
August 12, 2009 Theratechnologies to receive a milestone payment of US $10 million associated with the FDA acceptance to file tesamorelin NDA
July 7, 2009 Theratechnologies Announces Financial Results and Highlights for the Second Quarter 2009
June 19, 2009 Theratechnologies awarded Le Prix Santé by the Fondation Armand-Frappier
June 12, 2009 Theratechnologies presents results from a pharmacokinetic/phamacodynamic evaluation of tesamorelin at the Endocrine Society’s Annual Meeting
June 1, 2009 Theratechnologies files a New Drug Application for tesamorelin with the US Food and Drug Administration
April 27, 2009 Theratechnologies presents additional data from studies evaluating tesamorelin at the Annual Canadian Conference on HIV/AIDS Research
March 26, 2009 Theratechnologies’ annual and special meeting of shareholders
March 25, 2009 Theratechnologies announces financial results of the first quarter 2009
February 9, 2009 2008: A PIVOTAL YEAR FOR THERATECHNOLOGIES
February 9, 2009 Theratechnologies presents data on patients with atherogenic lipid profile from its combined Phase 3 studies at CROI
January 9, 2009 Theratechnologies announces Senior Management Change
December 16, 2008 Theratechnologies Closes its Collaboration and Licensing Transaction with Emd Serono
December 15, 2008 Theratechnologies Announces Expiry of the Waiting Period Under the Hart-Scott Rodino Act
December 15, 2008 Theratechnologies Reports 52-Week Results in its Confirmatory Phase 3 Trial with Tesamorelin
November 13, 2008 Theratechnologies: Last Patient Treated in the Extension Phase of the Confirmatory Study Testing Tesamorelin in HIV-Associated Lipodystrophy
November 6, 2008 Theratechnologies Presents Additional Results from its Tesamorelin Phase 3 Studies at The 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
October 29, 2008 Theratechnologies and EMD Serono Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
October 9, 2008 Theratechnologies Announces Financial Results and Highlights For the Third Quarter 2008
September 2, 2008 Theratechnologies Announces Publication In AIDS
August 4, 2008 Theratechnologies Reports on Positive Body Image Parameters at The International AIDS Conference
July 9, 2008 Theratechnologies Announces Financial Results and Highlights For the Second Quarter 2008
June 20, 2008 Theratechnologies Comments on Current Market Activity
June 18, 2008 Theratechnologies Reports Positive 26-Week Results for its Second Tesamorelin Phase 3 Trial
May 15, 2008 Theratechnologies Explores Tesamorelin in Growth Hormone Deficient Abdominal Obesity
May 12, 2008 Theratechnologies and PDC Biotech Gmbh Sign License Agreement for Family of Peptides for Preterm Labour and Primary Dysmenorrhea Programs
April 17, 2008 Theratechnologies Receives the 2008 Genesis Innovation Award
April 14, 2008 Theratechnologies: Last Patient Treated in the Confirmatory Study Testing Tesamorelin in HIV-Associated Lipodystrophy
March 25, 2008 Theratechnologies announces financial results and highlights of the first quarter 2008
February 13, 2008 Theratechnologies Closes $29,750,000 Financing
February 6, 2008 Theratechnologies Presents Additional Results From its Tesamorelin 52-Week Phase 3 Study at the Conference on Retroviruses and Opportunistic Infections
February 5, 2008 Theratechnologies Files Final Base Shelf Prospectus and Prospectus Supplement
January 31, 2008 Theratechnologies Announces Common Share Offering
January 29, 2008 Theratechnologies Announces Review of Strategic Alternatives and Filing of Preliminary Base Shelf Prospectus for up to $35 Million Equity Financing
January 23, 2008 2007: A Year of Major Accomplishments for Theratechnologies
January 8, 2008 Theratechnologies Extends Patent Protection for Tesamorelin in the Treatment of HIV-Associated Lipodystrophy
December 10, 2007 Theratechnologies Estimates the Market Size for Hivassociated Lipodystrophy is between $811m and $1.3b in 2012
December 5, 2007 Theratechnologies announces publication of its 26-week Phase 3 data with tesamorelin in the New England Journal of Medicine
October 26, 2007 Theratechnologies Launches Awareness Program in HIV-Associated Lipodystrophy at the European Aids Conference
October 10, 2007 Theratechnologies Reports Third Quarter Results and Recent Corporate Highlights
October 9, 2007 Theratechnologies Announces Acceptance of Late Breaker Abstract at the 11th European AIDS Conference
October 1, 2007 Theratechnologies Reports Positive 52-Week Phase 3 Results for its Lead Drug Candidate Tesamorelin
September 26, 2007 Theratechnologies Announces a License Agreement for its Glucagon-Like Peptide-1 (Glp-1) Portfolio of Compounds
September 11, 2007 Theratechnologies Learns From the FDA That its Tesamorelin Clinical Program is Moving in the Right Direction
September 4, 2007 Theratechnolgoies Completes Patient Recruitment for Tesamorelin in Confirmatory Phase 3 Trial
August 9, 2007 Theratechnologies Appoints Dr. Pierre Caudrelier as Chief Medical Officer
August 3, 2007 Theratechnologies to present at the 27th Annual Canaccord Adams Global Growth Conference in Boston
July 18, 2007 TH9507 Phase 3 clinical update at international HIV meeting: • TH9507 improved the perception of belly image
July 17, 2007 Theratechnologies Regains Japanese Rights for TH9507
July 10, 2007 Additional Milestones Achieved for Theratechnologies in Second Quarter 2007
June 4, 2007 TH9507 Phase 3 Clinical Update
May 29, 2007 Theratechnologies Receives the National Biotechnology Award "Company of the Year"
May 2, 2007 Last Patient Treated in First Pivotal TH9507 Study
March 29, 2007 Theratechnologies’ Annual Meeting
March 28, 2007 Theratechnologies Enjoys Strong Momentum in First Quarter 2007
March 1, 2007 Results from TH9507 Phase 3 Study in HIV-Associated Lipodystrophy Presented at the 14th Conference on Retroviruses and Opportunistic Infections
February 27, 2007 Theratechnologies Closes $57, 750,000 Bought Deal Financing
February 21, 2007 Over-Allotment Option Increases Gross Proceeds Of Financing to $57,750,000
February 19, 2007 Theratechnologies Files a Final Prospectus
February 12, 2007 Theratechnologies Files Preliminary Prospectus
February 8, 2007 2006: A year of noteworthy progress for Theratechnologies
February 6, 2007 Theratechnologies Enters Into a Bought Deal Agreement for $52,500,000
December 19, 2006 Theratechnologies Reports Positive Phase 3 Results for TH9507 in HIV Associated Lipodystrophy
October 25, 2006 Theratechnologies: last patient treated in pivotal TH9507 trial
October 12, 2006 Theratechnologies: Financial results for third quarter of 2006 and recent operating highlights
August 23, 2006 Theratechnologies receives Special Protocol Assessment from FDA for second pivotal Phase 3 trial with TH9507
July 6, 2006 Independent Data Safety Monitoring Board recommends continuation of Phase 3 trial with TH9507
July 5, 2006 Theratechnologies: Financial results for second quarter of 2006 and recent operating highlights
April 20, 2006 Theratechnologies raises additional gross proceeds of $1.35 million through exercise of over-allotment option
March 30, 2006 Theratechnologies’ CEO Upbeat on Future Prospects
March 29, 2006 Theratechnologies: First Quarter 2006 Financial Results and Recent Highlights
March 28, 2006 University of Washington to conduct clinical trial with Theratechnologies’ TH9507 - NIH providing US $2.6 million to finance the project
March 23, 2006 Theratechnologies completes patient enrollment for TH9507 in first Phase 3 trial - Results Expected by End of Year
March 21, 2006 Theratechnologies closes $20 475 000 bought deal
March 14, 2006 Theratechnologies files a final prospectus
March 8, 2006 Theratechnologies files preliminary prospectus
March 2, 2006 Theratechnologies enters into a bought deal agreement for $20,475,000
February 8, 2006 Theratechnologies appoints former Montreal Stock Exchange President and CEO to its Board of Directors
February 8, 2006 Theratechnologies achieves key milestones in 2005
January 13, 2006 Theratechnologies Notes Passind of Board Membre Andre Delambre
January 9, 2006 Theratechnologies Comments on Stock Activity